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Abstract: Eosinophils are important inflammatory
cells in allergic diseases. In the present study, we
have investigated the effects of CCL22 on the re-
cruitment of eosinophils in vivo and in vitro.
CCL22 induced a dose- and time-dependent re-
cruitment of eosinophils into the pleural cavity of
mice, and this was dependent on the release of
platelet-activating factor (PAF) and subsequent
generation of CCL11. However, in an allergic pleu-
risy model, an anti-CCL22 polyclonal antibody
given during sensitization or before challenge had
no significant effect on eosinophil recruitment.
CCL22 did not induce eosinophil chemotaxis in
vitro but was able to induce eosinophil degranula-
tion in vitro and in vivo. In conclusion, we show
that although exogenously added CCL22 may in-
duce eosinophil migration in vivo via release of
PAF and CCL11 (eotaxin), endogenous production
of CCL22 does not drive eosinophil migration dur-
ing allergic inflammation. However, CCL22 may
be an important activator of eosinophils once these
cells have migrated into tissue. J. Leukoc. Biol. 73:
356–362; 2003.
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INTRODUCTION
Macrophage-derived chemokine (CCL22/MDC) is a CC che-
mokine that binds to CCR4 receptors primarily characterized
on T helper cell type 2 (TH2) cells [1]. CCL22 is a potent
chemoattractant to a variety of cells, including T cells, natural
killer (NK) cells, monocytes, and dendritic cells (DC), and
increases the bactericidal activity of macrophage [1, 2]. Earlier
studies have shown that CCL22 is constitutively expressed on
immune cells [3] and may be involved in the trafficking of
cells, generation, and amplification of type 2 responses [1].
More recently, Lloyd et al. [4] showed an important role for
CCL22 and its receptors in TH2 lymphocyte recruitment in a
model of allergic airway inflammation.
There is much evidence suggesting an important role for
eosinophils in the pathophysiology of allergic disease [5–7]. In
allergic disease, such as asthma, eosinophils are a crucial
source of cytotoxic proteins, lipid mediators, oxygen metabo-
lites, and cytokines, which contribute to severity of disease [8].
Thus, an understanding of mechanisms involved in the recruit-
ment of eosinophils may permit new therapies for eosinophil-
associated diseases. Eosinophil recruitment in sites of allergic
inflammation depends on the concerted action of a variety of
molecules including the chemokines, such as CCL11 (eotaxin)
and CCL5 [regulated on activation, normal T expressed and
secreted (RANTES)], and lipid mediators, such as leukotriene
B4 (LTB4) and platelet-activating factor (PAF) [9–14]. Re-
cently, CCL22 was shown to be an activator of human eosin-
ophil chemotaxis [15]. In this study, we have investigated the
effects of CCL22 on the recruitment of murine eosinophils in
vivo and in vitro and whether CCL22 works directly or indi-
rectly to mediate eosinophil recruitment. Finally, the effects of
anti-CCL22 antibodies on the recruitment of eosinophils in




Wild-type (WT) and PAF receptor-deficient (PAFR/) male BALB/c mice
(18–22 g) were used throughout these experiments. Animals were housed in a
temperature-controlled room with free access to water and food. PAFR/
mice were generated as described previously [16] and intercrossed for at least
seven generations to establish the BALB/c strain. These animals have been
kindly donated by Dr. Satoshi Ishii (University of Tokyo, Japan) and were bred
in the animal facilities of this institution.
Drugs and reagents
Recombinant murine (rm)CCL22 was purchased from Peprotech (London, UK).
CCL22 was diluted in phosphate-buffered saline (PBS; pH 7.4) containing
0.01% bovine serum albumin (BSA) and was stored at –70°C until use. BSA,
ovalbumin (OVA), and control rabbit serum were purchased from Sigma
Chemical Co. (St. Louis, MO). The LTB4 antagonist CP105,696 and the
specific and long-acting PAFR antagonist UK-74,505 were a gift from Pfizer
Global Research and Development (Kent, UK). CP105,696 was dissolved in
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dimethyl sulfoxide and further diluted in PBS. UK-74,505 was dissolved in
HCl 0.01N and further diluted in PBS. Control animals received drug vehicle.
Anti-CCL22 and anti-CCL11 antibodies
Rabbit anti-CCL22 antibody and anti-CCL11 antibody were prepared by
multiple-site immunization of New Zealand white rabbits with rmCCL22 or
CCL11 (R&D Systems, Minneapolis, MN) in complete Freund’s adjuvant.
Polyclonal antibodies were titered by direct enzyme-linked immunosorbent
assay (ELISA) and specifically verified by failure to cross-react to m interleu-
kin (IL)-3, mIL-1, m tumor necrosis factor  (TNF-), CCL3 [m macrophage-
inflammatory protein-1 (MIP-1)], IL-6, CCL2 [m homologue of monocyte
chemoattractant protein-1 (MCP-1)], CCL8 (mMIP-1), CCL2 [human
(h)MCP-1], CXCL8 (hIL-8), hRANTES, hMIP-1, hTNF. The immunoglobulin
G (IgG) portion of the serum was purified over a protein A column and stored
at –20°C in PBS until use.
Sensitization
Animals were immunized with OVA adsorbed to an aluminum hydroxide gel,
as described previously [17]. Briefly, mice were injected subcutaneously (s.c.)
on days 1 and 8 with 0.2 ml solution containing 100 g OVA and 70 g
aluminum hydroxide (Reheiss, Dublin, Ireland).
Leukocyte migration into the pleural cavity
induced by CCL22 or antigen
CCL22 (10–100 ng/cavity) was injected intrapleurally (i.pl.) in naive WT or
PAFR/ mice, and animals were killed at 24 h after the i.pl. injection.
Sensitized mice were challenged with antigen (OVA) or PBS. The cells present
in the pleural cavity were harvested by injecting 2 ml PBS and total cell counts
performed in a modified Neubauer chamber using Turk’s stain. Differential cell
counts were performed on cytospin preparations (Shandon III) stained with
May-Grumwald-Giemsa using standard morphologic criteria to identify cell
types. The results are presented as the number of cells per cavity.
Anti-CCL22 or anti-CCL11 pretreatment
The role of endogenous chemokines on eosinophil recruitment induced by
CCL22 or in the allergic pleurisy was investigated by using anti-CCL22,
anti-CCL11, or control IgG. The IgG fraction of a rabbit polyclonal anti-CCL22
antibody or anti-CCL11 antibody or the IgG portion of serum of preimmune
rabbits was prepared purified over a protein A column, as described previously
[18]. Anti-CCL22 was administered intraperitoneally (i.p.) at the dose of 100
g/mouse 60 min before the i.pl. administration of CCL22 or OVA, and
anti-CCL11 was administered i.p. at the dose of 100 g/mouse 60 min before
the i.pl. administration of CCL22. Control animals received preimmune IgG.
LTB4 receptor antagonist and PAFR
antagonist pretreatment
To investigate the role of LTB4 and PAF on the eosinophil recruitment induced
by CCL22, the LTB4 receptor antagonist CP105,696 (3 mg/Kg) or the PAFR
antagonist UK-74,505 (1 mg/Kg) was administered i.p. 60 min before the
stimulus. Control animals received drug vehicle.
Antigen elicited peritoneal eosinophil purification
Eosinophils were induced by the injection of thioglycolate plus soluble egg
antigen (SEA) into the peritoneum of Schistosoma mansoni-infected mice. SEA
was prepared in our laboratory by grinding isolated eggs from heavily infected
S. mansoni-infected mice as described previously [19]. This injection induces
a pool of circulating eosinophils recruited into the peritoneum in an antigen-
specific manner. After 48 h, the peritoneum of mice was lavaged, and cells
were collected. The initial population that is isolated from the peritoneum is
50% eosinophils with only 2–5% neutrophils and 35–45% mononuclear
cells (lymphocytes and macrophages). Adherent cell populations were removed
from the population by plastic adherence in tissue-culture dishes for 1 h. The
nonadherent cells were washed and resuspended in PBS/BSA (90 l PBS/BSA
per 107 cells), and eosinophils were purified by negative immunomagnetic
bead-coupled antibodies to exclude contaminating immune cells using the
magnetic cell sorter (MACS) system. The antibodies used were anti-Thy1 (for
T cells), anti-B220 (for B cells) and anti-class II (for antigen-presenting cells).
After the plate adherence and MACS separation, the population of cells
contained 97% eosinophils with contaminating neutrophils (1%) and
mononuclear cells (1–2%).
In vitro chemotaxis
Eosinophil migration was quantitated by a modification of a Boyden chamber
technique, as described previously [20]. Purified eosinophils were suspended
at 3  106 cells/ml in Dulbecco’s PBS plus 0.5% BSA and were placed in the
top wells of the microchemotaxis chamber. Bottom wells were filled with CC
chemokines (CCL11 and CCL22) in the final concentration of 10 and 100
ng/ml, respectively, or assay medium as negative control. A 5-m pore-size
polycarbonate filter separated the upper wells containing the cells from the
control and chemokine samples in the bottom wells. The chambers were
incubated for 1 h at 37°C in a 5% CO2 moist atmosphere, and the filters were
then carefully scraped of nonmigrating cells, fixed with methanol, and stained
with Diff-Quik. Eosinophil migration was quantitated by counting the number
of eosinophils migrating completely through the matrix-coated filter in 10
high-powered fields (HPF) in triplicate samples. The data are expressed as the
average number of countable adherent cells per HPF (SEM).
Eosinophil degranulation in vitro and in vivo
To analyze eosinophil peroxidase (EPO) release in vitro, purified murine
eosinophil cells were resuspended in phenol red-free Dulbecco’s modified
Eagle’s medium and activated with chemokines (CCL11 and CCL22 in the final
concentration of 10 and 100 ng/ml, respectively, or assay medium as negative
control) for 4 h. The supernatant from the activated cells (2106 eosinophils)
was harvested, and the EPO level in the cell-free supernatant was determined
as described previously [21]. Eosinophil viability, as assessed by trypan blue
exclusion, was consistently greater than 98% in control eosinophils or after
stimulation by CCL11 or CCL22. To evaluate eosinophil degranulation in vivo,
sensitized mice received an i.pl. injection of CCL22 or CCL11, 48 h after the
challenge of the pleural cavity with antigen. After a further 2 h, cell-free
supernatants were obtained from pleural cavity washes, and EPO levels were
evaluated as described previously [21]. Briefly, o-phenyldiamine (OPD) (10
mg) was dissolved into 5.5 ml dH2O, and 1.5 ml OPD solution was added to 8.5
ml of a Tris buffer (pH 8.0) followed by the addition of 7.5 l H2O2. Using a
96-well plate, 100 l substrate solution was added to a 50 l sample. After 30
min, the reaction was quenched with 50 l 4 M H2SO4, and the absorbance
was read at 490 nm. The relative increase in samples was then compared. As
a positive control, eosinophils (2106 cells) were sonicated and measured as
total EPO. A negative control was used by sonicating neutrophils (2106).
Statistical analysis
All results are presented as the mean  SEM. Normalized data were analyzed
by one-way ANOVA, and differences between groups were assessed using
Student-Newman-Keuls’ post-test. A P value 	0.05 was considered signifi-
cant.
RESULTS
CCL22 induces the migration of eosinophils into
the pleural cavity
The i.pl. injection of CCL22 (10–100 ng/cavity) induced a
dose-dependent recruitment of eosinophils after 24 h (Fig.
1A). CCL22 was not specific for eosinophils, as it also induced
recruitment of neutrophils and mononuclear cells (Table 1).
Maximal eosinophil recruitment occurred between 24 and 48 h
after injection of CCL22, and the number of cells decreased
thereafter (Fig. 1B). In the next series of experiments, CCL22
was used at the dose of 100 ng/cavity, and recruitment of
eosinophils was assessed 24 h after challenge.
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Role of LTB4, PAF, and CCL11 on CCL22-
induced eosinophil recruitment
We then investigated the role of endogenous LTB4 and PAF in
the eosinophil recruitment induced by CCL22. Naı̈ve mice
were pretreated with the LTB4 receptor antagonist CP105,696
(3 mg/Kg) or the PAFR antagonist UK-74,505 (1 mg/Kg) 1 h
before the i.pl. injection of CCL22, and the number of eosin-
ophils was assessed 24 h later. The pretreatment with the
PAFR antagonist UK-74,505 but not with the LTB4 receptor
antagonist CP105,696 inhibited eosinophil recruitment in-
duced by CCL22 injection (Fig. 2). Similar to the effects of the
PAFR antagonist, CCL22 failed to induce eosinophil recruit-
ment in PAFR/ mice (WT mice–PBS, 0.40.1 eosino-
phils105/cavity; CCL22 100 ng, 3.11.8; PAFR/ mice–
PBS, 0.20.1; CCL22, 0.120.03; n
5 in each group). These
results suggest that PAF is a chemotactic mediator involved in
CCL22-induced eosinophil recruitment.
PAF has been shown to release CCL11 into the pleural
cavity of naı̈ve mice and to mediate the release of the latter
protein following antigen challenge of sensitized mice [9]. As
PAF is an intermediate in the eosinophil recruitment induced
by CCL22, we examined whether the release of CCL11 was
also involved in this process. Pretreatment of mice with an
anti-CCL11 polyclonal antibody effectively inhibited (81%
inhibition) the recruitment of eosinophils observed after injec-
tion of CCL22 (Fig. 3).
CCL22 is not involved in the migration of
eosinophils in allergic reaction in the pleural
cavity of mice
The i.pl. injection of 1 g OVA/cavity in sensitized mice
induced a PAF- and CCL11-dependent recruitment of eosin-
ophils into the pleural cavity of mice [9, 10, 22]. As CCL22
induces and functions via the release of PAF and CCL11, we
then investigated the possible involvement of endogenous
CCL22 in this model of allergic inflammation. Pretreatment of
animals with a purified anti-CCL22 polyclonal antibody (100
g IgG/animal) had no significant effect on the recruitment of
eosinophils to the pleural cavity of allergen-challenged animals
(Fig. 4). Similarly, administration of higher doses of anti-
CCL22 (300 g IgG/animal) also failed to affect eosinophil
recruitment after antigen challenge (OVA 1 g, 2.620.92;
OVAanti-CCL22 300 g, 2.520.24; P0.05, n
4). How-
ever, pretreatment of animals with anti-CCL22 1 h before
challenge abrogated eosinophil recruitment induced by CCL22
(Fig. 4).
As CCL22 is a chemoattractant for DC and is involved in the
normal positioning of these cells in tissue and lymphoid organs
Fig. 1. Dose-response (A) and time-course (B) effects of CCL22 on the recruitment of eosinophil to the pleural cavity of mice. For the dose-response experiments
(A), CCL22 was administered at the indicated doses, and the number of infiltrating eosinophil was assessed after 24 h. For time-course experiments (B), 100 ng
CCL22 was administered i.pl., and eosinophil recruitment was assessed 4, 24, 48, and 72 h after injection. The results are expressed as means  SEM of five mice
in each group. *, P 	 0.05 when compared with controls.
TABLE 1. Total and Differential Cell Counts (x105 Cells/Cavity) in Response to the i.pl. Injection of CCL22 in Naı̈ve Micea
Time (h)
4 24 48 72
PBS CCL22 PBS CCL22 PBS CCL22 PBS CCL22
Total 5.4  1.2 13.1  2.9 4.0  0.3 15.4  3.5* 5.7  0.2 17.1  1.8* 6.8  0.6 8.3  0.6
Mononuclear 4.9  1.1 6.2  1.2 3.4  0.2 12.1  2.3* 5.5  1.2 15.3  1.7* 6.7  0.6 7.5  0.7
Neutrophils 0.5  0.1 6.8  1.9* 0.3  0.1 2.2  0.8* 0.1  0.01 0.3  0.1 0 0
Eosinophils 0 0 0.3  0.1 1.1  0.3* 0.1  0.1 1.4  0.3* 0.1  0.03 0.8  0.1*
a CCL22 (100 ng in 100 l/cavity) or PBS (100 l/cavity) was administered i.pl. in mice, and leukocyte migration was assessed at 4, 24, 48, and 72 h after
injection. The results are expressed as means  SEM of five mice in each group. * P  0.05 when compared with PBS.
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[1], we administered anti-CCL22 antibodies during sensitiza-
tion. Treatment of animals 1 h before and 24 h after sensiti-
zation with antigen did not cause any changes in allergen-
induced recruitment of eosinophils into the pleural cavity (Fig.
5). The splenic cells of these animals were stimulated in vitro,
and the concentrations of interferon- (IFN-) and IL-5 in
culture supernatants were measured by specific ELISA. Treat-
ment with anti-CCL22 had little effect in the concentration of
these cytokines in culture supernatant (IL-5, IgG control,
793.8280.64 pg/ml; anti-CCL22, 832.9339.78 pg/ml;
IFN-, IgG control, 1018.0396.12 pg/ml; anti-CCL22,
1837.95178.4 pg/ml; P0.05, n
4). Moreover, the antibody
failed to cause any variation of IgG1 titers measured in the
serum of these animals (IgG control, 0.1440.02; anti-CCL22,
0.1550.01, absorbance at 492 nm; P0.05, n
4).
CCL22 is involved in eosinophil activation
To determine the ability of CC chemokine CCL22 to induce
chemotaxis of antigen-elicited murine eosinophils, we used a
classic two-chamber assay. Antigen-elicited eosinophils mi-
grated toward CCL11 but not to CCL22 in two different con-
centrations (Fig. 6). However, different from CCL11, CCL22
was able to induce eosinophil degranulation in a dose-depen-
dent manner, as assessed by the release of EPO from eosino-
phils upon activation with CCL22 (Fig. 7A). The release of
EPO from eosinophils upon activation with CCL22 was approx-
imately 60% of the total eosinophil EPO content (data not
Fig. 2. Effects of the LTB4 receptor antagonist CP105,696 and PAFR antag-
onist UK-74,505 on the eosinophil recruitment induced by CCL22. Mice were
pretreated with CP105,696 (CP; 3 mg/Kg) and UK-74,505 (UK; 1 mg/Kg) i.p.
60 min before the i.pl. injection of CCL22 (100 ng/cavity) in naı̈ve mice, and
the number of infiltrating eosinophil was assessed after 24 h. The control group
of mice was injected with vehicle. The results are expressed as means  SEM
of five mice in each group. *, P 	 0.05 when compared with PBS; #, P 	 0.01
when compared with vehicle-treated animals.
Fig. 3. Effects of an anti-CCL11 polyclonal antibody on the recruitment of
eosinophils induced by CCL22. Mice were pretreated with nonimmune IgG
(400 g, i.p.) or purified anti-CCL11 polyclonal antibody (400 g, i.p.) 60 min
before the i.pl. injection of CCL22 (100 ng/cavity) in naı̈ve mice, and the
number of infiltrating eosinophils was assessed after 24 h. The control group of
mice was injected with PBS. The results are expressed as means  SEM of six
mice in each group. *, P 	 0.01 when compared with PBS.
Fig. 4. Effects of anti-CCL22 pretreatment on the recruitment of eosinophil
induced by antigen (Ova) challenge in sensitized mice or CCL22. Anti-CCL22
(hyperimmune Ig, 100 g/animal) or nonimmune, purified Ig (100 g/animal)
was injected i.pl. 1 h before the i.pl. injection of CCL22 (100 ng/cavity) or
OVA (1 g/cavity), and the number of infiltrating eosinophils was assessed
after 24 h injection of MDC and after 48 h injection of OVA. The results are
expressed as means  SEM of five mice in each group. *, P 	 0.05 when
compared with PBS; #, P 	 0.01 when compared with animals injected with
nonimmune IgG.
Fig. 5. Effects of treatment with anti-CCL22 antibodies during the sensitiza-
tion phase on recruitment of eosinophil induced by OVA challenge in sensi-
tized mice. Anti-CCL22 was injected 1 h before and 24 h after s.c. injection of
OVA, and the number of infiltrating eosinophils was assessed after 48 h
challenge with OVA. The results are expressed as means  SEM of five mice
in each group. *, P 	 0.05 when compared with controls.
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shown). To extend on the observation that CCL22 may be an
important activator of eosinophils, experiments were performed
in vivo. After 48 h, the levels of EPO in the pleural cavity of
antigen-challenged mice were only slightly greater than that in
pleural cavities of PBS-challenged, sensitized mice (Fig. 7B).
However, if sensitized mice received an i.pl. injection of
CCL22 or CCL11 at this time point (48 h after antigen chal-
lenge), and EPO levels were evaluated after a further 2 h, there
was a marked increase in levels of EPO in pleural cavity
washes of CCL22- but not CCL11-injected mice (Fig. 7B).
These data suggest that CCL22 is a potent stimulus for eosin-
ophil degranulation but not for eosinophil chemotaxis.
DISCUSSION
An important feature of allergic disease is the presence of a
great number of eosinophils in tissue [5]. In asthma, an in-
creased number of eosinophils have been found in bronchoal-
veolar lavage and bronchial biopsies [5–7, 23]. Similarly, eo-
sinophil-derived products are commonly found in skin biopsies
of patients with allergic dermatitis [24, 25]. Although the role
of eosinophils in asthma is not completely understood, it is
thought that the recruitment and action of eosinophils in the
airways may underlie several of the pathophysiological mani-
festations of asthma [5, 7, 8]. An understanding of the mech-
anisms and role of chemokines and mediators that regulate
chemokine production involved in eosinophil recruitment may
be essential for the development of pharmacological therapies
to control allergic disease. In this study, we evaluated the
effects on and relevance of CCL22 for eosinophil migration in
vivo and in vitro.
Here, we demonstrated that the injection of CCL22 caused a
dose- and time-dependent recruitment of eosinophils into the
pleural cavity of mice. Maximal eosinophil recruitment oc-
curred 24 h after injection of a dose of 100 ng/cavity of the
chemokine. These effects of CCL22 were qualitatively similar
to the shown effects of other chemokines, including CCL3,
CCL5, and CCL11 [10]. Previous studies have demonstrated
the involvement of lipid mediators, such as LTB4 and PAF, in
the eosinophil recruitment induced by a range of inflammatory
stimuli and following i.pl. administration of the chemokines [9,
10, 26]. Thus, we investigated whether CCL22 acted directly to
induce eosinophil recruitment or did so by inducing the local
release of lipid mediators. The treatment of mice with the LTB4
receptor antagonist CP105,696 had no significant effect on the
eosinophil recruitment induced by CCL22. This is in contrast
with the significant inhibitory effects of the treatment with a
PAFR antagonist UK-74,505 and in agreement with other
studies showing the involvement of PAF in the migration of
eosinophils in vivo [9, 27–29]. Thus, it appears that the ability
of CCL22 to induce eosinophil recruitment is dependent on the
release of PAF. More recently, we have shown that PAF-
Fig. 7. Effects of CCL22 and CCL11 on the degranulation of (A) antigen-
elicited murine eosinophils in vitro and (B) in the allergic pleurisy model. (A)
CCL22 and CCL11 were used at the concentrations of 10 or 100 ng/ml.
Purified eosinophils were activated for 4 h with the chemokines, and degran-
ulation was assessed by measuring the EPO levels in the cell-free supernatant.
(B) Sensitized mice received an i.pl. injection of PBS, CCL22 (100 ng/cavity),
or CCL11 (100 ng/cavity) 48 h after antigen challenge, and EPO levels in
pleural cavity washes were evaluated after a further 2 h. The line represents
background levels after injection of PBS in sensitized, unchallenged mice. The
results are expressed as the means  SEM of triplicate determinations and are
representative of at least three different experiments. *, P 	 0.01 when
compared with PBS or eotaxin. O.D., Optical density.
Fig. 6. Effects of CCL22 and CCL11 on the chemotaxis of antigen-elicited
murine eosinophils. CCL22 and CCL11 were used at the concentrations of 10
or 100 ng/ml. Purified eosinophils were incubated for 1 h at 37°C in a 5% CO2
moist atmosphere with chemokines. Eosinophil migration was quantitated by
counting the number of eosinophils migrating completely through the matrix-
coated filter in 10 HPF. The results are expressed as the means  SEM of
triplicate determinations and are representative of at least three different
experiments. *, P 	 0.01 when compared with PBS.
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induced eosinophil recruitment is dependent on the release of
CCL11 into the pleural cavity [9]. In agreement with these
studies, pretreatment with anti-CCL11 antibody effectively in-
hibited the recruitment of eosinophils induced by CCL22. In
the present study, we have been unable to detect CCL11
immunoreactivity in pleural cavity fluid of naı̈ve animals after
injection of CCL22 (data not shown). This is in contrast with
the effects of the anti-CCL11 antibody in the system. However,
we have previously shown that low concentrations of CCL11
may synergize with PAF to induce eosinophil recruitment [9].
It is thus possible that the amount of CCL11 present in the fluid
is sufficient to cooperate with PAF to induce eosinophil re-
cruitment but not detectable using our ELISA technique. Thus,
the injection of CCL22 into the pleural cavity of naı̈ve mice
appears to trigger the release of PAF and sequential generation
of CCL11, which ultimately induces eosinophil recruitment in
our system. The inability of CCL22 to induce murine eosino-
phil chemotaxis in vitro supports the notion that intermediate
mediators are needed for the in vivo effects of CCL22 on
eosinophil recruitment.
As CCL22 induced eosinophil recruitment when injected
exogenously and was capable of inducing PAF and CCL11,
both important mediators during allergic inflammation [9, 28–
32], we evaluated the relevance of CCL22 for eosinophil re-
cruitment in our allergic pleurisy model. Pretreatment with an
anti-CCL22 polyclonal antibody, at a dose that effectively
blocked the effects of CCL22 itself, had no inhibitory effect on
the recruitment of eosinophils induced by antigen challenge of
sensitized mice. This is qualitatively similar to the lack of
effects of anti-CCL22 for the migration of eosinophils into the
airway lumen in an allergic model of asthma [33]. In addition,
mice that are deficient in CCR4, the receptor for CCL22,
showed similar lung recruitment of eosinophils to WT controls
[34]. In contrast, CCL22 was relevant for the initial but not late
migration of eosinophils in an animal model of asthma [33].
Thus, although CCL22 can induce the recruitment of eosino-
phils in a PAF- and CCL11-dependent manner when added
exogenously, it appears that endogenous release of CCL22
plays only a minor role in determining eosinophil recruitment
in models of allergic inflammation.
As CCL22 acts on diverse cellular targets including DC, NK
cells, and T cell subsets [1], it may affect the sensitization
phase of an allergic immune response. Treatment with the
anti-CCL22 antibody during the sensitization phases had no
significant effect on the eosinophil accumulation induced by
antigen challenge. Moreover, we failed to observe any signifi-
cant modification of the production of cytokines by spleen cell
cultures, including IFN- and IL-5. In agreement with the lack
of importance for CCL22 during the sensitization phase,
CCR4-deficient mice were also immunized and responded
normally in a model of allergic asthma [34].
Although anti-CCL22 failed to affect eosinophil migration
consistently, it was found to block the development of airway
hyper-responsiveness in the murine model of asthma [33]. One
possibility that stems from the latter observations is that
CCL22 may activate eosinophils (and possibly other cell
types), which have migrated to the tissues. In support of the
latter possibility, we demonstrate here that elicited eosinophils
degranulated in response to activation by CCL22 but not
CCL11 in vitro and in vivo. Whether CCL22 activates human
eosinophils in a similar manner is not known. Of note, Bochner
et al. [15] have shown that CCL22 induced the chemotaxis of
eosinophils purified from blood of allergic patients. The effect
of CCL22 was independent on CCR3 (blocking antibody did
not reverse the effects) or CCR4 (no mRNA for CCR4 on
eosinophils) and thus, was dependent on a receptor distinct
from CCR1 to 7 [15]. The inability of CCL22 to induce che-
motaxis of murine eosinophils suggests that this latter, distinct
chemokine receptor is absent on murine eosinophils or does
not respond to CCL22 in this species. Similarly, although
RANTES (CCL5) stimulates human eosinophils, it fails to
activate murine eosinophils [12]. Thus, it is clear that in human
eosinophils, CCL22 may not only activate eosinophil degran-
ulation (as shown here for murine eosinophils) but also their
chemotaxis, suggesting a role for this chemokine in human
allergic diseases.
There are other CC chemokines, including CCL17/thymus
and activation-regulated chemokine, CCL8/MIP-1, and
CCL1/trichloroacetic acid-3, which are capable of preferen-
tially inducing eosinophil activation rather than eosinophil
migration (ref. [35]; and S. H. Oliveira et al., unpublished
results). It is interesting that the opposite was observed with
CCL11, which preferentially induced eosinophil migration over
eosinophil activation, as assessed by degranulation. Thus, it
appears that during the allergic process, specific chemokines
may be important to induce eosinophil recruitment to sites of
inflammation. Once there, eosinophils may come in contact
with tissue matrix and locally produced mediators, become
activated, express new chemokine receptors, and respond dif-
ferentially to various chemokines [35, 36]. Moreover, an im-
portant point not to be missed is the observation that two
distinct chemokines acting on the same cell type trigger dis-
tinct functions, highlighting the complexity and cooperation of
chemokines in in vivo systems. Whether differential signaling
transduction pathways regulate the differential response of
eosinophils to the various chemokines clearly deserves further
investigation.
In conclusion, we show that although exogenously added
CCL22 may induce eosinophil migration in vivo via the se-
quential release of PAF and CCL11, endogenous production of
CCL22 does not drive eosinophil migration during allergic
inflammation. However, CCL22 may be an important activator
of eosinophils once these cells have migrated into tissue.
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